Ligand Pharmaceuticals (NASDAQ:LGND) Director Sells $636,340.00 in Stock

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Get Free Report) Director Martine Zimmermann sold 2,000 shares of the business’s stock in a transaction that occurred on Thursday, November 12th. The stock was sold at an average price of $318.17, for a total value of $636,340.00. Following the transaction, the director directly owned 1,782 shares in the company, valued at $566,978.94. The trade was a 52.88% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Martine Zimmermann also recently made the following trade(s):

  • On Thursday, September 10th, Martine Zimmermann sold 1,200 shares of Ligand Pharmaceuticals stock. The shares were sold at an average price of $285.00, for a total value of $342,000.00.

Ligand Pharmaceuticals Stock Performance

Shares of NASDAQ:LGND traded down $7.08 on Monday, hitting $301.71. The company had a trading volume of 186,903 shares, compared to its average volume of 263,991. The stock has a market cap of $6.04 billion, a price-to-earnings ratio of 134.69, a P/E/G ratio of 5.39 and a beta of 1.16. The stock has a 50 day moving average price of $301.71 and a 200 day moving average price of $258.02. Ligand Pharmaceuticals Incorporated has a 1-year low of $175.89 and a 1-year high of $326.63. The company has a current ratio of 1.22, a quick ratio of 1.19 and a debt-to-equity ratio of 0.71.

Ligand Pharmaceuticals (NASDAQ:LGND – Get Free Report) last posted its earnings results on Thursday, October 29th. The biotechnology company reported $2.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.33 by $0.34. Ligand Pharmaceuticals had a net margin of 20.27% and a return on equity of 5.22%. The company had revenue of $78.75 million during the quarter, compared to analysts’ expectations of $77.00 million. During the same quarter last year, the company posted $3.09 EPS. Ligand Pharmaceuticals’s quarterly revenue was down 31.8% compared to the same quarter last year. Analysts expect that Ligand Pharmaceuticals Incorporated will post 2.35 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the company. Royal Bank Of Canada upped their target price on Ligand Pharmaceuticals from $345.00 to $357.00 and gave the company an “outperform” rating in a research report on Friday, October 30th. Citigroup boosted their price target on Ligand Pharmaceuticals from $397.00 to $402.00 and gave the company a “buy” rating in a research note on Thursday, November 5th. Weiss Ratings lowered Ligand Pharmaceuticals from a “buy (b)” rating to a “hold (c)” rating in a report on Monday, November 2nd. HC Wainwright reiterated a “buy” rating and set a $358.00 price objective on shares of Ligand Pharmaceuticals in a research report on Thursday, September 24th. Finally, Leerink Partners assumed coverage on Ligand Pharmaceuticals in a report on Friday, August 14th. They set an “outperform” rating and a $330.00 target price for the company. Eight analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat.com, Ligand Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $355.38.

Get Our Latest Stock Analysis on LGND

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Global Retirement Partners LLC increased its position in Ligand Pharmaceuticals by 2.5% in the 3rd quarter. Global Retirement Partners LLC now owns 1,403 shares of the biotechnology company’s stock valued at $438,000 after acquiring an additional 34 shares during the period. GAMMA Investing LLC raised its stake in shares of Ligand Pharmaceuticals by 5.7% during the second quarter. GAMMA Investing LLC now owns 681 shares of the biotechnology company’s stock valued at $215,000 after acquiring an additional 37 shares during the last quarter. Choreo LLC raised its stake in shares of Ligand Pharmaceuticals by 3.0% during the third quarter. Choreo LLC now owns 1,634 shares of the biotechnology company’s stock valued at $510,000 after acquiring an additional 47 shares during the last quarter. Cim Investment Management Inc. lifted its holdings in shares of Ligand Pharmaceuticals by 3.4% during the first quarter. Cim Investment Management Inc. now owns 1,484 shares of the biotechnology company’s stock worth $296,000 after purchasing an additional 49 shares during the period. Finally, Ethic Inc. lifted its holdings in shares of Ligand Pharmaceuticals by 7.4% during the third quarter. Ethic Inc. now owns 1,002 shares of the biotechnology company’s stock worth $313,000 after purchasing an additional 69 shares during the period. 91.28% of the stock is owned by institutional investors.

About Ligand Pharmaceuticals

(Get Free Report)

Ligand Pharmaceuticals is a biopharmaceutical company that works with pharmaceutical and biotechnology partners to develop and commercialize medicines. Rather than focusing primarily on selling drugs directly, Ligand licenses technologies and drug-development assets and may receive royalties and other payments from partner programs. Its technologies include Captisol, a formulation platform designed to improve the solubility and delivery of certain medicines. Ligand also holds economic interests in a portfolio of partnered products and drug candidates across multiple therapeutic areas.

Further Reading

Insider Buying and Selling by Quarter for Ligand Pharmaceuticals (NASDAQ:LGND)

Receive News & Ratings for Ligand Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ligand Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.